Ixekizumab-induced urticarial drug eruption.

ABSTRACT: Biological agents targeting inflammatory skin diseases have dramatically overcome many of the limitations of older oral therapeutic options. Among the various biological agents, ixekizumab is a humanised monoclonal antibody that blocks the biological activity of IL-17A, which exhibited high efficacy against psoriasis. Although there are a limited number of cutaneous adverse reactions, biologic-induced type I allergic reactions are rare. Herein, we report a case of ixekizumab-induced urticaria.

SUBMITTER: Kaneoka A 

PROVIDER: S-EPMC10549868 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature